Arcturus Therapeutics Holdings (ARCT) Payables (2018 - 2026)

Arcturus Therapeutics Holdings has reported Payables for 9 years, with the latest figure at $4.1 million in Q1 2026.

• For the quarter ending Q1 2026, Payables fell 33.76% year-over-year to $4.1 million; the trailing twelve-month figure through Mar 2026 stood at $4.1 million (down 33.76% YoY), and the FY2025 full-year result was $4.2 million, down 41.13% from the prior year.
• Payables for Q1 2026 stood at $4.1 million, down from $4.2 million in the prior quarter.
• The five-year high for Payables was $19.3 million in Q1 2023, with the low at $4.1 million in Q1 2026.
• Historically, Payables has averaged $9.9 million across 5 years, with a median of $9.1 million in 2024.
• Annual changes were most pronounced in 2023 — Payables jumped 136.36% — and 2024, when it sank 52.73%.
• Arcturus Therapeutics Holdings' Payables stood at $7.4 million in 2022, then declined by 29.13% to $5.3 million in 2023, then surged by 36.28% to $7.2 million in 2024, then plunged by 41.13% to $4.2 million in 2025, then fell by 3.35% to $4.1 million in 2026.
• The last three Payables figures came in at $4.1 million (Q1 2026), $4.2 million (Q4 2025), and $5.5 million (Q3 2025), per Business Quant data.